<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02066467</url>
  </required_header>
  <id_info>
    <org_study_id>Rally X4-10-2013</org_study_id>
    <nct_id>NCT02066467</nct_id>
  </id_info>
  <brief_title>Maximizing CRT Delivery by Using MultipolAr Coronary Sinus Lead FamiLy ACUITY® X4 - RALLY X4 Study</brief_title>
  <acronym>RallyX4</acronym>
  <official_title>Maximizing CRT Delivery by Using Multipolar Coronary Sinus Lead Family ACUITY® X4</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to collect clinical data on safety and performance of ACUITY
      X4® leads when used in a standard clinical setting.

      It is a prospective, non-randomized, observational multicenter study evaluating standard of
      care.

      For Post Market Clinical Follow up (PMCF) purposes the 3 month implant success rate, adverse
      events and basic parameters of the lead will be assessed. The cohort of subjects included in
      this evaluation will be the first 200 subjects which are indicated for PMCF in Rally X4 to
      receive an ACUITY X4® lead implant.

      Study endpoints:

      Phrenic Nerve Stimulation (PNS) related CFR through 6 months post-implant (Defined as: rate
      of freedom from loss of function or operative system revision due to unacceptable PNS
      threshold) Lead-related Complication-Free Rate (CFR) from Implant through 3 months
      post-implant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinic visits will occur at:

        -  Enrollment and Consenting Clinic Visit (≤ 30 days prior to implant procedure)

        -  Implant Procedure (Day 0; all future follow ups based on this date)

        -  Pre-Discharge Clinic Visit (≤ 7 days post implant procedure) (Required)

        -  One to 6 Month Clinic Visit (20 to 180 days post implant procedure) (Required)

        -  Interim Visit(s) (Any time between the 1 to 6 Month Clinic Visit and Close-out Clinic
           Visit) (Following study center specific standard of care) (Device follow up optional) AE
           - reporting required

        -  Close-out Clinic Visit (30 months ± 90 days, OR 180 days ± 90 days after the study is
           closed to enrollment, whichever comes first) (Required)

        -  During the trial all AEs, deaths, and changes in the device system must be reported

        -  Devices of subjects who have received a Latitude device will be followed by the Boston
           Scientific (BSC) Latitude team. Device Data as defined in the Clinical Investigation
           Plan (CIP), device alerts, and diagnostic data from the standard Latitude database may
           be collected and entered into the study database at any time.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2014</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Phrenic Nerve Complication Free Rate</measure>
    <time_frame>6 months post-implant</time_frame>
    <description>The Phrenic Nerve Stimulation (PNS) related Complication Free rate (CFR) through 6 months post-implant is defined as the rate of freedom from loss of function or operative system revision due to unacceptable PNS threshold</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3 Month Lead-related Complication-Free Rate (CFR)</measure>
    <time_frame>3 months post-implant</time_frame>
    <description>Lead-related Complication-Free Rate (CFR) from implant through 3 months post-implant. Lead-related complications associated with the ACUITY X4® lead were counted towards this endpoint.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>3 Month Implant Success Rate for Indicated Subjects</measure>
    <time_frame>3 months post-implant</time_frame>
    <description>Post Market Clinical Follow-up (PMCF) of the ACUITY X4® lead was evaluated in this study. The outcome of interest is the 3 month implant success rate. The cohort of subjects included in this evaluation is the first 200 subjects to receive an ACUITY X4® lead implant and meet the PMCF eligibility criteria outlined below. The outcomes of interest for the PMCF supplemental analysis is the percent of subjects successfully implanted with an ACUITY X4® lead.
Implant success is defined as the ability of the ACUITY X4® lead to be implanted and deliver CRT therapy. Subjects who have multiple lead implant attempts during the procedure, but are eventually successfully implanted with the ACUITY X4® lead and receive CRT therapy are classified as a successful implant.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">863</enrollment>
  <condition>Heartfailure</condition>
  <arm_group>
    <arm_group_label>Heart failure patients</arm_group_label>
    <description>Subjects with art failure who receive stable optimal pharmacologic therapy
Moderate to severe heart failure (NYHA Class III-IV) with ejection fraction (EF) ≤ 35% and QRS duration ≥ 120 ms
Left bundle branch block (LBBB) with QRS duration ≥ 130 ms, EF ≤ 30%, and mild (NYHA Class II) ischemic or non-ischemic heart failure or asymptomatic (NYHA Class I) ischemic heart failure.
The study is collecting observational data on regular CRT-D device implants with special focus on the left ventricular ACUITY X4® Lead Family' .</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Left Ventricular lead implant: ACUITY X4® Lead Family</intervention_name>
    <description>Implantation of (cardiac re-synchronization therapy with defibrillator) CRT-D devices for heartfailure treatment</description>
    <arm_group_label>Heart failure patients</arm_group_label>
    <other_name>Autogen™X4 CRT-D G179-200 G177-200</other_name>
    <other_name>Dynagen™ X4 CRT-D G158-200 G156-200</other_name>
    <other_name>Inogen™ X4 CRT-D G148-200 G146-200</other_name>
    <other_name>Origen™ X4 CRT-D G058-200 G056-200</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The BSC Cardiac Resynchronization Therapy Defibrillators (CRT-Ds) are indicated for
        subjects with art failure who receive stable optimal pharmacologic therapy (OPT) for heart
        failure and who meet any one of the following classifications:

          -  Moderate to severe heart failure (New York Heart Association (NYHA) Class III-IV) with
             ejection fraction (EF) ≤ 35% and QRS duration ≥ 120 ms

          -  Left bundle branch block (LBBB) with QRS duration ≥ 130 ms, EF ≤ 30%, and mild (NYHA
             Class II) ischemic or non-ischemic heart failure or asymptomatic (NYHA Class I)
             ischemic heart failure BSCCRT-Ds are also intended to provide ventricular
             antitachycardia pacing and ventricular defibrillation for automated treatment of
             life-threatening ventricular arrhythmias.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is willing and capable of providing informed consent

          2. Subject is planned to be implanted with an ACUITY X4® lead for left-ventricular pacing
             and sensing via the coronary venous system in conjunction with a compatible BSC pulse
             generator

          3. Subject is willing and capable of participating in all visits associated with this
             study at an approved clinical study center and at the intervals defined by this CIP

          4. Subject is age 18 or above, or of legal age to give informed consent specific to state
             and national law

        Exclusion Criteria:

          1. Subjects with a hypersensitivity to a maximum single dose of 0.51 mg dexamethasone
             acetate

          2. Subject is enrolled in any other concurrent study without prior written approval from
             BSC, with the exception of local mandatory governmental registries and observational
             studies/registries that are not in conflict and do not affect the following:

               -  Schedule of procedures for the RALLY X4 Study (i.e. should not cause additional
                  or missed visits);

               -  RALLY X4 Study outcome (i.e. involve medications that could affect the heart rate
                  of the subject);

               -  Conduct of the RALLY X4 Study per GCP/ ISO 14155:2011/ local regulations as
                  applicable

          3. Per the implanting physician's discretion, the subject is not a suitable candidate to
             receive the study device as determined during the implant procedure

          4. Women of childbearing potential who are or might be pregnant at the time of study
             enrollment or ACUITY X4® lead implant.

          5. Subject is unwilling or unable to participate in all scheduled study follow up visits
             at an approved study center

          6. Subject does not anticipate being a resident of the area for the scheduled duration of
             the trial

          7. Subject's physician does not allow participation

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haran Burri, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Cantonal de Genève</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Torsten Kayser</last_name>
    <role>Study Chair</role>
    <affiliation>Boston Scientific Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Landesklinikum St.Pölten</name>
      <address>
        <city>St.Pölten</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guidant Europe SA / NV a Boston Scientific Company</name>
      <address>
        <city>Diegem</city>
        <zip>1831</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundation Cardioinfantil</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Valle del Lili</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Medellin</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gentofte Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Skejby</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier d'Annecy</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nouvelles Cliniques Nantaises</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Pau</name>
      <address>
        <city>Pau</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Nordrhein-Westfalen</name>
      <address>
        <city>Bad Oeynhausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unfallkrankenhaus Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waldklinikum Gera</name>
      <address>
        <city>Gera</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz-und Gefäßzentrum Göttingen</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Kassel</name>
      <address>
        <city>Kassel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Landshut-Achdorf</name>
      <address>
        <city>Landshut</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waterfort Hospital</name>
      <address>
        <city>Waterford</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barzilai Medical Center</name>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beilinson Medical Center</name>
      <address>
        <city>Petah Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Rechovot</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Sant'Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Vittorio Emanuele</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Pugliese Ciaccio</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Spedale Sant'Anna di Como</name>
      <address>
        <city>Como</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Montevergine</name>
      <address>
        <city>Mercogliano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria Misericordia</name>
      <address>
        <city>Rovigo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Borgo Trento</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansai Rosai Hospital</name>
      <address>
        <city>Amagasaki-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokai University Hospital</name>
      <address>
        <city>Isehara-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shonan Kamakura General Hospital</name>
      <address>
        <city>Kamakura-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kokura Memorial Hospital</name>
      <address>
        <city>Kitakyushu-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyorin University Hospital</name>
      <address>
        <city>Mitaka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka General Medical Center</name>
      <address>
        <city>Osaka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Police Hospital</name>
      <address>
        <city>Osaka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakurabashi Watanabe Hospital</name>
      <address>
        <city>Osaka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Rosai Hospital</name>
      <address>
        <city>Sakai-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama City University Hospital</name>
      <address>
        <city>Yokohama-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Alkmaar</name>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Rijnstate</name>
      <address>
        <city>Arnheim</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Vila Nova de Gaia</name>
      <address>
        <city>Gaia</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar do Alto Ave</name>
      <address>
        <city>Guimaraes</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Cruz</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Maria</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar do Porto</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changi General Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Heart Centre</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doce De Octubre University Hospital</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vírgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Valladolid</name>
      <address>
        <city>Valladolid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cantonal de Genève</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institution Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elisabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Golden Jubilee National Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Colombia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>February 7, 2014</study_first_submitted>
  <study_first_submitted_qc>February 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2014</study_first_posted>
  <results_first_submitted>August 14, 2018</results_first_submitted>
  <results_first_submitted_qc>August 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 20, 2019</results_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phrenic Nerve Stimulation</keyword>
  <keyword>Heartfailure treatment</keyword>
  <keyword>CRT-D therapy</keyword>
  <keyword>Quadripolar lead</keyword>
  <keyword>Lead related complication free rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first subject was enrolled on 10 February 2014. The clinical phase of the study was completed on 30 September 2016 which was the date of the last subject's close-out visit. A total of 863 subjects across 82 centers were enrolled in the study in Europe, Asia and South America.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Heart Failure Patients</title>
          <description>Subjects with heart failure who receive stable optimal pharmacologic therapy
Moderate to severe heart failure (NYHA Class III-IV) with ejection fraction (EF) ≤ 35% and QRS duration ≥ 120 ms
Left bundle branch block (LBBB) with QRS duration ≥ 130 ms, EF ≤ 30%, and mild (NYHA Class II) ischemic or non-ischemic heart failure or asymptomatic (NYHA Class I) ischemic heart failure.
The study is collecting observational data on regular CRT-D device implants with special focus on the left ventricular ACUITY X4® Lead Family' .
Left Ventricular lead implant: ACUITY X4® Lead Family: Implantation of (cardiac re-synchronization therapy with defibrillator) CRT-D devices for heartfailure treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="863"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="648"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="215"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not undergo implant procedure</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Attempted to implant withoput success</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent ineligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not defined</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Heart Failure Patients</title>
          <description>Subjects with heart failure who receive stable optimal pharmacologic therapy
Moderate to severe heart failure (NYHA Class III-IV) with ejection fraction (EF) ≤ 35% and QRS duration ≥ 120 ms
Left bundle branch block (LBBB) with QRS duration ≥ 130 ms, EF ≤ 30%, and mild (NYHA Class II) ischemic or non-ischemic heart failure or asymptomatic (NYHA Class I) ischemic heart failure.
The study is collecting observational data on regular CRT-D device implants with special focus on the left ventricular ACUITY X4® Lead Family' .
Left Ventricular lead implant: ACUITY X4® Lead Family: Implantation of (cardiac re-synchronization therapy with defibrillator) CRT-D devices for heartfailure treatment</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="863"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="863"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.5" spread="10.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="863"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="189"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="674"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Colombia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="863"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Singapore</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="863"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hong Kong</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="863"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="863"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="863"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="863"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Portugal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="863"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="863"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="863"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="863"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="863"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ireland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="863"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="863"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="863"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="863"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="863"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="863"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="863"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Phrenic Nerve Complication Free Rate</title>
        <description>The Phrenic Nerve Stimulation (PNS) related Complication Free rate (CFR) through 6 months post-implant is defined as the rate of freedom from loss of function or operative system revision due to unacceptable PNS threshold</description>
        <time_frame>6 months post-implant</time_frame>
        <population>795 patients successfully implanted with ACUITY X4 lead</population>
        <group_list>
          <group group_id="O1">
            <title>Heart Failure Patients</title>
            <description>Subjects with heart failure who receive stable optimal pharmacologic therapy
Moderate to severe heart failure (NYHA Class III-IV) with ejection fraction (EF) ≤ 35% and QRS duration ≥ 120 ms
Left bundle branch block (LBBB) with QRS duration ≥ 130 ms, EF ≤ 30%, and mild (NYHA Class II) ischemic or non-ischemic heart failure or asymptomatic (NYHA Class I) ischemic heart failure.
The study is collecting observational data on regular CRT-D device implants with special focus on the left ventricular ACUITY X4® Lead Family' .
Left Ventricular lead implant: ACUITY X4® Lead Family: Implantation of (cardiac re-synchronization therapy with defibrillator) CRT-D devices for heartfailure treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Phrenic Nerve Complication Free Rate</title>
          <description>The Phrenic Nerve Stimulation (PNS) related Complication Free rate (CFR) through 6 months post-implant is defined as the rate of freedom from loss of function or operative system revision due to unacceptable PNS threshold</description>
          <population>795 patients successfully implanted with ACUITY X4 lead</population>
          <units>% of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="795"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5" lower_limit="98.8" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>exact binominal methodology</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>3 Month Lead-related Complication-Free Rate (CFR)</title>
        <description>Lead-related Complication-Free Rate (CFR) from implant through 3 months post-implant. Lead-related complications associated with the ACUITY X4® lead were counted towards this endpoint.</description>
        <time_frame>3 months post-implant</time_frame>
        <population>795 patients successfully implanted with ACUITY X4 lead</population>
        <group_list>
          <group group_id="O1">
            <title>Heart Failure Patients</title>
            <description>Subjects with heart failure who receive stable optimal pharmacologic therapy
Moderate to severe heart failure (NYHA Class III-IV) with ejection fraction (EF) ≤ 35% and QRS duration ≥ 120 ms
Left bundle branch block (LBBB) with QRS duration ≥ 130 ms, EF ≤ 30%, and mild (NYHA Class II) ischemic or non-ischemic heart failure or asymptomatic (NYHA Class I) ischemic heart failure.
The study is collecting observational data on regular CRT-D device implants with special focus on the left ventricular ACUITY X4® Lead Family' .
Left Ventricular lead implant: ACUITY X4® Lead Family: Implantation of (cardiac re-synchronization therapy with defibrillator) CRT-D devices for heartfailure treatment</description>
          </group>
        </group_list>
        <measure>
          <title>3 Month Lead-related Complication-Free Rate (CFR)</title>
          <description>Lead-related Complication-Free Rate (CFR) from implant through 3 months post-implant. Lead-related complications associated with the ACUITY X4® lead were counted towards this endpoint.</description>
          <population>795 patients successfully implanted with ACUITY X4 lead</population>
          <units>% of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="795"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8" lower_limit="98" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>3 Month Implant Success Rate for Indicated Subjects</title>
        <description>Post Market Clinical Follow-up (PMCF) of the ACUITY X4® lead was evaluated in this study. The outcome of interest is the 3 month implant success rate. The cohort of subjects included in this evaluation is the first 200 subjects to receive an ACUITY X4® lead implant and meet the PMCF eligibility criteria outlined below. The outcomes of interest for the PMCF supplemental analysis is the percent of subjects successfully implanted with an ACUITY X4® lead.
Implant success is defined as the ability of the ACUITY X4® lead to be implanted and deliver CRT therapy. Subjects who have multiple lead implant attempts during the procedure, but are eventually successfully implanted with the ACUITY X4® lead and receive CRT therapy are classified as a successful implant.</description>
        <time_frame>3 months post-implant</time_frame>
        <population>At data cutoff date on 16 November 2015, 201 enrolled subjects met all of the PMCF eligibility criteria and were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Heart Failure Patients</title>
            <description>Subjects with heart failure who receive stable optimal pharmacologic therapy
Moderate to severe heart failure (NYHA Class III-IV) with ejection fraction (EF) ≤ 35% and QRS duration ≥ 120 ms
Left bundle branch block (LBBB) with QRS duration ≥ 130 ms, EF ≤ 30%, and mild (NYHA Class II) ischemic or non-ischemic heart failure or asymptomatic (NYHA Class I) ischemic heart failure.
The study is collecting observational data on regular CRT-D device implants with special focus on the left ventricular ACUITY X4® Lead Family' .
Left Ventricular lead implant: ACUITY X4® Lead Family: Implantation of (cardiac re-synchronization therapy with defibrillator) CRT-D devices for heartfailure treatment</description>
          </group>
        </group_list>
        <measure>
          <title>3 Month Implant Success Rate for Indicated Subjects</title>
          <description>Post Market Clinical Follow-up (PMCF) of the ACUITY X4® lead was evaluated in this study. The outcome of interest is the 3 month implant success rate. The cohort of subjects included in this evaluation is the first 200 subjects to receive an ACUITY X4® lead implant and meet the PMCF eligibility criteria outlined below. The outcomes of interest for the PMCF supplemental analysis is the percent of subjects successfully implanted with an ACUITY X4® lead.
Implant success is defined as the ability of the ACUITY X4® lead to be implanted and deliver CRT therapy. Subjects who have multiple lead implant attempts during the procedure, but are eventually successfully implanted with the ACUITY X4® lead and receive CRT therapy are classified as a successful implant.</description>
          <population>At data cutoff date on 16 November 2015, 201 enrolled subjects met all of the PMCF eligibility criteria and were included in the analysis.</population>
          <units>% of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5" lower_limit="97.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>exact binominal methodology</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events are collected from 1st enrollment through study completion (last subject's close-out visit)</time_frame>
      <desc>All adverse events are collected as per ISO 14155:2011 and medical device guidance (MEDDEV) 2.7/3 12/2010 The number of participants at risk is defined as the subjects actively enrolled (838). Adverse events were not collected for subjects who did not undergo an implant procedure (24) and consent ineligible subjects (1).</desc>
      <group_list>
        <group group_id="E1">
          <title>Heart Failure Patients</title>
          <description>Subjects with heart failure who receive stable optimal pharmacologic therapy
Moderate to severe heart failure (NYHA Class III-IV) with ejection fraction (EF) ≤ 35% and QRS duration ≥ 120 ms
Left bundle branch block (LBBB) with QRS duration ≥ 130 ms, EF ≤ 30%, and mild (NYHA Class II) ischemic or non-ischemic heart failure or asymptomatic (NYHA Class I) ischemic heart failure.
The study is collecting observational data on regular CRT-D device implants with special focus on the left ventricular ACUITY X4® Lead Family' .
Left Ventricular lead implant: ACUITY X4® Lead Family: Implantation of (cardiac re-synchronization therapy with defibrillator) CRT-D devices for heartfailure treatment</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="338" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hematological</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic regurgitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation (AF)</sub_title>
                <counts group_id="E1" events="46" subjects_affected="41" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident (CVA)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Chest pain - Ischemic</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Chest pain - Other</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Distal thromboemboli</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Dyspnea - Heart failure</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Heart failure symptoms - Unspecified</sub_title>
                <counts group_id="E1" events="56" subjects_affected="49" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Mitral regurgitation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Mitral stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Multiple heart failure symptoms</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Multi-system failure - Heart failure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Nonsustained ventricular tachycardia (NSVT)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Other- Heart failure patient condition - Cardiovascular</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Other SVT (eg AVRT, AVNRT, EAT)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Peripheral edema - Heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disease</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Premature ventricular contractions (PVC)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Pulmonary edema - Heart failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism (PE)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Renal insufficiency - Heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Thromboembolic events</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack (TIA)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation (VF)</sub_title>
                <counts group_id="E1" events="15" subjects_affected="10" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia (VT)</sub_title>
                <counts group_id="E1" events="27" subjects_affected="17" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Weight gain - Heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="24" subjects_affected="20" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal laboratory values</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Adverse reaction - Allergic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Adverse reaction - Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Head, eyes, ears, nose, throat (HEENT)</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Intermittent Claudication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Multi-system failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Other- Patient condition - Non- cardiovascular</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Physical trauma</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Systemic infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device Deficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Dislodgment - Elevated threshold - LV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Dislodgment - Extracardiac stimulation- LV</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Dislodgment - Multiple signs - LV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Dislodgment - No reported signs - RA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Dislodgment - No reported signs - RV</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Dislodgment - No reported signs -LV</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Dislodgment - Unable to capture - LV</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Dislodgment - Unable to capture - RA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Dislodgment - Unable to capture - RV</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Elevated threshold - LV</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Elevated threshold - RV</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Erosion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Extracardiac stimulation - LV</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Extracardiac stimulation - RV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Impedance &gt; 2000 ohms - LV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Inappropriate tachy therapy - Noise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Inappropriate tachy therapy - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Inappropriate tachy therapy - SVT</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Inappropriate tachy therapy- NSR</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Infection (&gt; 30 days post-implant)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Myocardial perforation post-implant - RA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Myocardial perforation post-implant - RV</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Other - Lead</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Other - PG system</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Oversensing - RV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Pacemaker-mediated tachycardia (PMT)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Unable to capture - RA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychological</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD exacerbation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" events="28" subjects_affected="23" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Integumentary</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary venous dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Hematoma - Pocket (&lt;= 30 days post-implant)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Myocardial perforation with tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Myocardial perforation without tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Other - Lead - Procedure</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Other - PG system - Procedure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Pleural effusion - Procedure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Pneumothorax - Procedure</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Post-surgical infection (&lt;= 30 days post-implant)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Post-surgical pocket hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Post-surgical wound discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Venous occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial/venous thrombolytic event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="452" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hematological</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic regurgitation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation (AF)</sub_title>
                <counts group_id="E1" events="33" subjects_affected="30" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Chest pain - Heart failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Chest pain - Ischemic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Chest pain - Other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Dyspnea - Heart failure</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Heart failure symptoms - Unspecified</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Hematoma - Unrelated to procedure or device</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Hypertension - Heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Hypotension - Heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Multiple heart failure symptoms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Multiple symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Nonsustained ventricular tachycardia (NSVT)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Other- Heart failure patient condition - Cardiovascular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Other SVT (eg AVRT, AVNRT, EAT)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Pericarditis - Unrelated to procedure or device</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Peripheral edema - Heart failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Premature ventricular contractions (PVC)</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Thromboembolic events</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack (TIA)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Vasovagal reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation (VF)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia (VT)</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal laboratory values</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Adverse reaction - General</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Head, eyes, ears, nose, throat (HEENT)</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Other- Patient condition - Non- cardiovascular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Physical trauma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device Deficiency</sub_title>
                <counts group_id="E1" events="41" subjects_affected="33" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Dislodgment - Elevated threshold - LV</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Dislodgment - Elevated threshold -RV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Dislodgment - Multiple signs - LV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Dislodgment - No reported signs - RV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Dislodgment - No reported signs -LV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Dislodgment - Unable to capture - LV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Dislodgment - Unable to capture - RA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Dislodgment - Undersensing - RV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Elevated threshold - LV</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Elevated threshold - RA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Elevated threshold - RV</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Extracardiac stimulation - LV</sub_title>
                <counts group_id="E1" events="55" subjects_affected="47" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Extracardiac stimulation - RV</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Impedance &gt; 2000 ohms - LV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Impedance &gt; 2000 ohms - RA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Impedance &gt; 2000 ohms - RV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Inappropriate AV delay</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Inappropriate tachy therapy - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Inappropriate tachy therapy - SVT</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Infection (&gt; 30 days post-implant)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Other - Lead</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Other - PG system</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Oversensing - RV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Pacemaker-mediated tachycardia (PMT)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Rate response inappropriate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>RVAT Communication</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Unable to capture - LV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychological</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse reaction - Respiratory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Integumentary</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary venous dissection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Hematoma - Pocket (&lt;= 30 days post-implant)</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Hematoma - Pocket (&gt; 30 days post-implant)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Other - Lead - Procedure</sub_title>
                <counts group_id="E1" events="92" subjects_affected="87" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Other - PG system - Procedure</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Pleural effusion - Procedure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Pneumothorax - Procedure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Post-surgical wound discomfort</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="838"/>
              </event>
              <event>
                <sub_title>Venous occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="838"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 30 days from the time submitted to the sponsor for review. The sponsor can request changes to the communication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Caroline Beaudoint</name_or_title>
      <organization>Boston Scientific</organization>
      <phone>+32479904163</phone>
      <email>Caroline.Beaudoint@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

